Analyst Ratings For Madrigal Pharmaceuticals (NASDAQ:MDGL)
Today, Cowen initiated coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Outperform.
Some recent analyst ratings include
- 2/28/2018-Cowen initiated coverage with a Outperform rating.
- 2/8/2018-Evercore ISI Reiterated Rating of Outperform .
Recent Insider Trading Activity For Madrigal Pharmaceuticals (NASDAQ:MDGL)
Madrigal Pharmaceuticals (NASDAQ:MDGL) has insider ownership of 66.40% and institutional ownership of 27.13%.
- On 8/23/2017 Richard S Levy, Director, bought 2,000 with an average share price of $16.12 per share and the total transaction amounting to $32,240.00.
- On 8/22/2017 Richard S Levy, Director, bought 3,550 with an average share price of $16.12 per share and the total transaction amounting to $57,226.00.
- On 8/21/2017 Richard S Levy, Director, bought 3,550 with an average share price of $15.88 per share and the total transaction amounting to $56,374.00.
- On 12/14/2015 Keith R Gollust, Director, sold 600,000 with an average share price of $0.35 per share and the total transaction amounting to $210,000.00.
- On 12/9/2015 Keith R Gollust, Director, sold 745,892 with an average share price of $0.38 per share and the total transaction amounting to $283,438.96.
- On 12/8/2015 Bruce Kovner, Director, sold 1,523,346 with an average share price of $0.37 per share and the total transaction amounting to $563,638.02.
- On 12/3/2015 Bruce Kovner, Director, sold 1,430,753 with an average share price of $0.43 per share and the total transaction amounting to $615,223.79.
Recent Trading Activity for Madrigal Pharmaceuticals (NASDAQ:MDGL)
Shares of Madrigal Pharmaceuticals closed the previous trading session at 133.22 up +1.82 1.39% with 133.00999450683594 shares trading hands.